To sum up, dual blockade of CD47 and PD-1/PD-L1 shows synergistic anti-tumor effects, and this might be due to the fact that CD47 is co-expressed with PD-L1 in various cancers, and CD47 blockade promotes phagocytosis of macrophages and activates CD8+ T cells. Here, SNCA is linked to cancer.